Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate‐to‐severe atopic dermatitis: A nationwide retrospective cohort study
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.19794 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Gianluca Avallone und 45 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Pregnancy Complications, Pregnancy Outcome. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Background
There is limited epidemiological evidence on outcomes associated with dupilumab exposure during pregnancy; monitoring pregnancy outcomes in large populations is required.
Objective
To investigate the potential association between exposure to dupilumab in pregnant women with atopic dermatitis and any adverse pregnancy, neonatal, congenital and post‐partum outcomes.
Methods
We performed a multicentre retrospective cohort study across 19 Italian tertiary referral hospital. Childbearing women were eligible if aged 18–49 years and carried out the pregnancy between 1 October 2018 and 1 September 2022.
Results
We retrospectively screened records of 5062 patients receiving dupilumab regardless of age and gender, identifying 951 female atopic dermatitis patients of childbearing age, 29 of whom had been exposed to the drug during pregnancy (3%). The median duration of dupilumab treatment prior to conception was 22.5 weeks (range: 3–118). The median time of exposure to the drug during pregnancy was 6 weeks (range: 2–24). All the documented pregnancies were unplanned, and the drug was discontinued in all cases once pregnancy status was reported. The comparison of the study cohort and the control group found no significant drug‐associated risk for adverse pregnancy, congenital, neonatal or post‐partum outcomes. The absence of a statistically significant effect of exposure on the event was confirmed by bivariate analysis and multivariate analysis adjusted for other confounding factors.
Conclusions
This cohort of pregnant patients exposed to dupilumab adds to the existing evidence concerning the safety of biologic agents in pregnancy. No safety issues were identified regarding the primary outcome assessed. In clinical practice, these data provide reassurance in case of dupilumab exposure during the first trimester. However, the continuous use of dupilumab throughout pregnancy warrants further research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
- Obstetrics and Gynecology 1U, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, Sant Anna Hospital, University of Torino, Turin, Italy.
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
- Dermatology Section, Department of Medical, Surgical, and Neurological Sciences, Santa Maria Alle Scotte Hospital, University of Siena, Siena, Italy.
- Dermatology Department, University of Brescia, Brescia, Italy.
ORCID-Profile: Gianluca Avallone, Francesco Cavallo, Carlo A Maronese, Martina Bertello, Claudio Conforti, Giulia Calabrese, Luigi Gargiulo, Niccolò Gori, Laura Bonzano, Giovanni Paolino, Maddalena Napolitano, Caterina Ferreli, Luca Bettolini, Luca Mastorino, Giuseppe Argenziano, Ilaria Trave, Antonio Costanzo, Andrea Chiricozzi, Anna Balato, Angelo V Marzano, Simone Ribero, Pietro Quaglino
Zitieren
APA
Avallone, G., Cavallo, F., Tancredi, A., Maronese, C. A., Bertello, M., Fraghì, A., Conforti, C., Calabrese, G., Di Nicola, M. R., Oddenino, G. A., Gargiulo, L., Gori, N., Loi, C., Romita, P., Piras, V., Bonzano, L., Tolino, E., Paolino, G., Napolitano, M., …, & Quaglino, P. (2024). Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate‐to‐severe atopic dermatitis: A nationwide retrospective cohort study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19794
Vancouver
Avallone G, Cavallo F, Tancredi A, Maronese CA, Bertello M, Fraghì A, et al. Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate‐to‐severe atopic dermatitis: A nationwide retrospective cohort study. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19794
BibTeX
@article{Avallone2024,
author = {Avallone, Gianluca and Cavallo, Francesco and Tancredi, Annalisa and Maronese, Carlo A and Bertello, Martina and Fraghì, Alessandro and Conforti, Claudio and Calabrese, Giulia and Di Nicola, Matteo R and Oddenino, Giorgio A and Gargiulo, Luigi and Gori, Niccolò and Loi, Camilla and Romita, Paolo and Piras, Viviana and Bonzano, Laura and Tolino, Ersilia and Paolino, Giovanni and Napolitano, Maddalena and Patruno, Cataldo and Nettis, Eustachio and Ferreli, Caterina and Roccuzzo, Gabriele and Marozio, Luca and Silvio, Martina and Russo, Filomena and Bettolini, Luca and Gallo, Rosella and Mercuri, Santo R and Mastorino, Luca and Rossi, Mariateresa and Zalaudek, Iris and Argenziano, Giuseppe and Trave, Ilaria and Costanzo, Antonio and Chiricozzi, Andrea and Gurioli, Carlotta and Foti, Caterina and Potenza, Concetta and Ferrucci, Silvia M and Balato, Anna and Parodi, Aurora and Marzano, Angelo V and Ortoncelli, Michela and Ribero, Simone and Quaglino, Pietro},
title = {Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate‐to‐severe atopic dermatitis: A nationwide retrospective cohort study},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.19794}
}
EUVIMED